Biochemical Basis of Vosevi, a New Treatment for Hepatitis C.
作者信息
Besandre Ronald, Liu Hung-Wen
机构信息
Division of Chemical Biology and Medicinal Chemistry, College of Pharmacy, and Department of Chemistry, The University of Texas at Austin , Austin, Texas 78712, United States.
出版信息
Biochemistry. 2018 Feb 6;57(5):479-480. doi: 10.1021/acs.biochem.7b01157. Epub 2017 Nov 29.
Abstract
摘要
相似文献
1
Biochemical Basis of Vosevi, a New Treatment for Hepatitis C.
Biochemistry. 2018 Feb 6;57(5):479-480. doi: 10.1021/acs.biochem.7b01157. Epub 2017 Nov 29.
2
Mavyret: A Pan-Genotypic Combination Therapy for the Treatment of Hepatitis C Infection.
Biochemistry. 2018 Feb 6;57(5):481-482. doi: 10.1021/acs.biochem.7b01160. Epub 2017 Dec 1.
3
Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
Drugs. 2018 Apr;78(5):577-587. doi: 10.1007/s40265-018-0895-5.
4
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.
5
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
Lancet Gastroenterol Hepatol. 2018 Aug;3(8):559-565. doi: 10.1016/S2468-1253(18)30118-3. Epub 2018 May 31.
6
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
BMC Nephrol. 2019 Feb 4;20(1):36. doi: 10.1186/s12882-019-1218-0.
7
Mavyret and Vosevi--two new combinations for chronic HCV infection.
Med Lett Drugs Ther. 2017 Oct 9;59(1531):166-170.
8
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
J Hepatol. 2018 Dec;69(6):1221-1230. doi: 10.1016/j.jhep.2018.07.023. Epub 2018 Aug 9.
9
Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients.
Antivir Ther. 2019;24(1):1-10. doi: 10.3851/IMP3264.
10
Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection.
J Hepatol. 2022 Oct;77(4):1215-1217. doi: 10.1016/j.jhep.2022.06.024. Epub 2022 Jul 5.
引用本文的文献
1
Non-nucleoside structured compounds with antiviral activity-past 10 years (2010-2020).
Eur J Med Chem. 2022 Mar 5;231:114136. doi: 10.1016/j.ejmech.2022.114136. Epub 2022 Jan 19.
2
Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.
Expert Opin Pharmacother. 2018 May;19(7):749-757. doi: 10.1080/14656566.2018.1459567. Epub 2018 Apr 10.
本文引用的文献
1
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.
2
Global epidemiology and burden of HCV infection and HCV-related disease.
Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):122-132. doi: 10.1038/nrgastro.2016.176. Epub 2016 Dec 7.
3
Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.
Nat Rev Gastroenterol Hepatol. 2016 Jun;13(6):338-51. doi: 10.1038/nrgastro.2016.60. Epub 2016 May 5.
4
Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase.
Science. 2015 Feb 13;347(6223):771-5. doi: 10.1126/science.1259210.
5
Discovery and development of hepatitis C virus NS5A replication complex inhibitors.
J Med Chem. 2014 Mar 13;57(5):1643-72. doi: 10.1021/jm401793m. Epub 2014 Feb 3.
Zotero 插件